Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

by B2i | Mar 22, 2024 | Press Releases

GAITHERSBURG, Md., March 22, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

by B2i | Mar 5, 2024 | Press Releases

Webcast presentation to take place at 11:25am ETROCKVILLE, Md., March 05, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients...

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

by B2i | Feb 13, 2024 | Press Releases

ROCKVILLE, Md., Feb. 13, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“SHPH” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients...

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

by B2i | Jan 23, 2024 | Press Releases

ROCKVILLE, Md., Jan. 23, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

by B2i | Jan 8, 2024 | Press Releases

ROCKVILLE, Md., Jan. 8, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”) today announced they have received the ‘Safe to Proceed’ letter from the U.S. Food and Drug Administration (FDA) for the...